MedWatch

Cosmo struggles to find EU partners for promising acne drug

The new acne treatment has been called a breakthrough, but finding partners in the EU has not come easy for Cosmo Pharmaceuticals, which is based in Switzerland.

Photo: Rob Acket/EMA

A new acne treatment has been available in the US for months - but it is unclear when it will reach Europe.

The drug, which is a cream called Winlevi based on the active ingredient clascoterone, has been heralded as the first real breakthrough within acne treatment in almost 40 years.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs